For Biosensors, stents and an acquisition helped drive a stellar year

Singapore device company Biosensors said it generated healthy revenue and profit growth during its 2012 fiscal year, based in part on healthy sales of its Nobori drug eluting stent, licensed by Terumo, for which the company earns licensing revenue. Fully absorbing its purchase of JW Medical Systems and greater sales of interventional cardiology products also helped, the company noted. Biosensors booked $292.1 million in overall revenue during the fiscal year and $88.2 million in fourth quarter revenue, up 72% and 98%, respectively, compared to fiscal 2011. Net profit for the year also reached $101 million and $28.6 million for the quarter. Release

Suggested Articles

The drug that treats atrial fibrillation, flecainide, has been around since the '80s. Grace Colón, CEO of InCarda, thinks it needs a face-lift.

3M, maker of the ubiquitous Littmann stethoscope brand, has teamed up with Eko to create a new digital version that amplifies sounds and adds AI.

Study data from Medtronic showed more patients reported improvements in their chronic back pain after treatments with the devicemaker’s tiny implant.